OpenURL Connection Search

Select item for more details and to access through your institution.

Freeze‐dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies.
Published in:
American Journal of Hematology, 2022, v. 97, n. 3, p. 256, doi. 10.1002/ajh.26403
By:
- Ohanian, Maro;
- Cancelas, Jose A.;
- Davenport, Robertson;
- Pullarkat, Vinod;
- Hervig, Tor;
- Broome, Catherine;
- Marek, Kelly;
- Kelly, Mary;
- Gul, Zartash;
- Rugg, Neeta;
- Nestheide, Shawnagay;
- Kinne, Bridget;
- Szczepiorkowski, Zbigniew;
- Kantarjian, Hagop;
- Pehta, Joan;
- Biehl, Ruth;
- Yu, Anna;
- Aung, Fleur;
- Antebi, Ben;
- Fitzpatrick, Glen Michael
Publication type:
Article
Characterization and first-in-human clinical dose-escalation safety evaluation of a next-gen human freeze-dried plasma.
Published in:
2022
By:
- Cancelas, Jose A.;
- Nestheide, Shawnagay;
- Rugg, Neeta;
- Eckerman, Anna;
- Macdonald, Victor W.;
- L. Charles, Matthew;
- Markstrom, Luke;
- Atkinson, Andrew J.;
- King, Melissa R.;
- Snyder, Michele;
- Burgess, David;
- Murto, James;
- Valiyaveettil, Manoj K.;
- C. Pehta, Joan;
- Penegor, Stephen A.
Publication type:
journal article
Safety evaluation of a lyophilized platelet-derived hemostatic product.
Published in:
2018
By:
- Barroso, Jeffrey;
- Osborne, Barbara;
- Teramura, Gayle;
- Pellham, Esther;
- Fitzpatrick, Michael;
- Biehl, Ruth;
- Yu, Anna;
- Pehta, Joan;
- Slichter, Sherrill J.
Publication type:
journal article
Infusion of P-Capt prion-filtered red blood cell products demonstrate acceptable in vivo viability and no evidence of neoantigen formation.
Published in:
Transfusion, 2011, v. 51, n. 10, p. 2228, doi. 10.1111/j.1537-2995.2011.03133.x
By:
- Cancelas, Jose A.;
- Rugg, Neeta;
- Pratt, P. Gayle;
- Worsham, D. Nicole;
- Pehta, Joan C.;
- Banks, Kate;
- Davenport, Robertson D.;
- Judd, W. John
Publication type:
Article

Found: 4

Freeze‐dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies.

Characterization and first-in-human clinical dose-escalation safety evaluation of a next-gen human freeze-dried plasma.

Safety evaluation of a lyophilized platelet-derived hemostatic product.

Infusion of P-Capt prion-filtered red blood cell products demonstrate acceptable in vivo viability and no evidence of neoantigen formation.